On Saturday, November 19, the company announced acquisition of the Indian refractory business of Dalmia Bharat Refractories Limited (DBRL) for Rs 1,708 crore
Based on the issuance price of RHI Magnesita India at Rs 632.5029 per share, the share consideration had a value of approximately Rs 1,708 crore.
Sun Pharmaceutical Industries is the only other stock among the Sensex 30 and Nifty 50 that trades in the overbought category, technically.